Latest Conference Articles

Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.

The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.

Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.

Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.

Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.

Katherine has an exquisite instinct for understanding that there is a context to each patient’s diagnosis that is just as important to understand.

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, reinforcing it as a new SOC.

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC.

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

The COCOON dermatologic management regimen reduced the quality-of-life impact of Rybrevant/Lazcluze vs SOC treatment in patients with EGFR-mutated NSCLC.

Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.

Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.

Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy.

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09.

Participation in a structured exercise program following surgery and adjuvant chemo improved key survival end points in stage 3 and high-risk stage 2 CRC.

Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.

Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer.

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.

Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer.

Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.

Trodelvy plus Keytruda, when given in the frontline, extended survival without progression versus chemo plus Keytruda in PD-L1+ metastatic TNBC.

Second-line Enhertu improved key survival end points versus Cyramza plus paclitaxel for HER2+ gastric cancer or gastroesophageal junction adenocarcinoma.

Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when compared with Faslodex.

Braftovi and Erbitux plus chemotherapy improved survival without progression over standard therapy in BRAF V600E-mutant mCRC in the first-line setting.